This caught my eye. Don't know anything about ANDS but looks like a good result, no?
----------------
Anadys says drug slashes hepatitis B in trial
Tue Feb 14, 2006 5:11 PM ET
NEW YORK, Feb 14 (Reuters) - Anadys Pharmaceuticals Inc. <ANDS.O> on Tuesday said its experimental drug for hepatitis B cut levels of the virus by more than 99 percent in a small mid-stage trial involving patients who had already become resistant to standard treatment.
San Diego-based Anadys said the Phase II trial involved 59 patients who received one of five doses of its once-daily oral drug, code-named ANA380, for 12 weeks.
"Each of the patients in the study had been previously treated with lamivudine, the current standard of care for hepatitis B patients, and was documented to have genetically-encoded lamivudine resistance," Anadys said.
After three months, viral reductions of greater than 99.9 percent were seen among patients receiving the three highest doses of the Anadys drug.
The company, which is co-developing ANA380 with South Korea's L.G. Life Sciences, Ltd., said no serious side effects were seen among patients taking the drug during the trial.
The companies said they are planning larger clinical trials, given the promising findings of the mid-phase study.
--------------
snip |
